Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + Savolitinib in EGFR Mutated Osimertinib Resistant NSCLC With Low Copy Number MET Amplification
NCT07322783Phase 2Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Started Jan 2025; status: recruiting.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07322783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322783.